Evaxion receives fda fast-track designation for personalized cancer immunotherapy

Copenhagen, denmark, jan. 19, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that the u.s. food and drug administration (“fda”) has granted fast track designation for the company's personalized cancer therapy, evx-01, in combination with keytruda®.
EVAX Ratings Summary
EVAX Quant Ranking